Generate Biomedicines, Zealand Pharma Team on AI-Designed Metabolic Drugs

Generate Biomedicines and Zealand Pharma have entered a collaboration and license agreement to develop protein therapeutics for metabolic diseases, combining the Danish company's clinical focus with the AI-driven drug design capabilities of the Boston-based biotech.

Under the pact, the companies will work to create multispecific drug candidates engineered with tailored biological functions using Generate Biomedicines' proprietary generative AI platform. Zealand Pharma contributes deep expertise in metabolic health, a therapeutic area where the company has built clinical and commercial momentum. The deal structure reflects a trend toward co-development arrangements where one partner supplies platform technology while the other brings disease-area specificity and development infrastructure.

The collaboration targets the metabolic disease market, where obesity and related conditions have become priority areas for pharmaceutical development. Multispecific therapeutics—compounds that act on multiple biological targets simultaneously—have gained regulatory and clinical traction in recent years, particularly for complex metabolic disorders requiring coordinated physiological intervention. Generate's AI platform enables rapid design of such candidates by computationally modeling protein structures and functions before synthesis and testing.

For Generate Biomedicines, the agreement expands its partnerships beyond earlier collaborations and validates the commercial viability of its platform in a high-priority therapeutic area. For Zealand Pharma, the deal provides access to proprietary AI design tools without requiring internal development of such infrastructure, accelerating its pipeline in metabolic indications. The arrangement also positions both firms to compete in a category increasingly attractive to major pharmaceutical companies seeking novel mechanisms in obesity and metabolic dysfunction.

Terms of the agreement were not disclosed. The collaboration will operate under a governance structure typical of such arrangements, with joint steering committees overseeing candidate selection and development decisions. Revenue typically flows to the technology provider through upfront payments, milestone fees, and royalties on commercialized products, though specifics remain confidential.

The deal signals sustained confidence in AI-enabled drug design as a legitimate pathway to novel therapeutics, despite earlier skepticism about computational approaches in pharma. Success will depend on whether AI-generated candidates advance through clinical development at rates and with safety profiles competitive with traditionally designed drugs in metabolic disease.